This page is for patients who have had cataract surgery and are experiencing new or worsening blur at two to six weeks, and who want to understand whether cystoid macular oedema (CMO) may be the cause.
CMO Is Treatable, But Requires Early Diagnosis
CMO affects approximately 1-2% of uncomplicated cataract cases and resolves in 80-90% of patients with standard anti-inflammatory treatment. Cystoid macular oedema is a post-operative inflammatory response in which fluid accumulates in the central retina, the macula, following cataract surgery. It is the most common cause of unexpectedly poor vision at two to six weeks in an otherwise uncomplicated case. The typical presentation is a patient who had good early vision post-operatively, then notices blur returning or worsening at the two to four week mark, with reduced visual acuity on formal testing.
CMO is treatable. Anti-inflammatory eye drops, topical NSAIDs and topical steroids, resolve the oedema in the majority of cases within four to six weeks of diagnosis. The critical variable is how quickly the diagnosis is made. CMO identified at two weeks and treated promptly produces full visual recovery in most patients. CMO identified at twelve weeks with established chronic oedema has a more guarded prognosis.
Who Is at Risk
CMO risk is elevated in patients with diabetes (particularly those with pre-existing diabetic maculopathy), uveitis, or a history of previous retinal surgery. It is also more common following complicated cataract surgery, particularly cases where posterior capsule rupture occurred intraoperatively. In straightforward phacoemulsification without these risk factors, the CMO incidence is approximately 1-2% in published series.
At Blue Fin Vision® clinic, Mr Mfazo Hove screens all high-risk patients with macular OCT before surgery to establish a baseline. Post-operatively, any patient presenting with unexplained blur at two to six weeks receives an OCT at the assessment visit to confirm or exclude CMO. This is the fastest and most definitive diagnostic test available, the cross-sectional retinal image shows oedema within minutes of the scan.
Treatment and Prognosis
First-line treatment: topical NSAID (e.g. ketorolac) four times daily plus topical steroid (e.g. prednisolone) four times daily, continued for six to eight weeks with review at four weeks. Response rate: approximately 80-90% of acute CMO cases resolve completely with this regimen.
Second-line treatment: intravitreal anti-VEGF injection or sub-Tenon steroid injection for refractory cases. These are managed in conjunction with Professor Mahmut Dogramaci (Consultant Vitreoretinal Surgeon) at Blue Fin Vision®, who provides subspecialty support for complex post-operative retinal complications.
Clinical Perspective
CMO is often not mentioned at pre-operative cataract consultations, the incidence is low enough that including it in every consent discussion risks creating unnecessary anxiety. At Blue Fin Vision®, it is specifically discussed with high-risk patients (diabetics, uveitis history, post-vitreoretinal surgery) and included in the written post-operative care guide as a named cause of late-onset blur. The instruction is clear: if vision worsens or fails to improve between week two and week six, seek review.
Clinical Takeaway
CMO is the most common cause of unexpected blur at two to six weeks post-cataract surgery. Incidence is approximately 1-2% in uncomplicated cases; higher in diabetic and uveitic patients. Diagnosis by OCT is immediate. First-line treatment with topical anti-inflammatory drops achieves resolution in 80-90% of cases. At Blue Fin Vision®, high-risk patients receive pre-operative macular OCT and post-operative CMO awareness guidance. If you develop new blur at two to six weeks after cataract surgery, book an OCT review at Blue Fin Vision® rather than waiting, early treatment produces significantly better outcomes than late diagnosis.
References
- Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema: risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33(9):1550-8.
- Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557-634.
- Belair ML, Kim SJ, Thorne JE, Dunn JP, Kedhar SR, Brown DM, Jabs DA. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol. 2009;148(1):128-35.
- Lobo CL, Faria PM, Soares MA, Bernardes RC, Cunha-Vaz JG. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg. 2004;30(4):752-60.
- Perente I, Utine CA, Ozturker C, Cakir M, Kaya V, Eren H, Ozkan B, Aslan BS. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr Eye Res. 2007;32(3):241-7.
